Recent advances in the treatment of C. difficile using biotherapeutic agents
Vo Van Giau,1 Hyon Lee,2 Seong Soo A An,1 John Hulme11Department of BioNano Technology, Gachon University, Seongnam-si 461-701, Republic of Korea; 2Department of Neurology, Gachon University Gil Medical Center, Incheon, South KoreaAbstract: Clostridium difficile (C. difficile) is rapidly becoming on...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-06-01
|
| Series: | Infection and Drug Resistance |
| Subjects: | |
| Online Access: | https://www.dovepress.com/recent-advances-in-the-treatment-of-c-difficile-using-biotherapeutic-a-peer-reviewed-article-IDR |
| _version_ | 1828778693500076032 |
|---|---|
| author | Giau VV Lee H An SSA Hulme J |
| author_facet | Giau VV Lee H An SSA Hulme J |
| author_sort | Giau VV |
| collection | DOAJ |
| description | Vo Van Giau,1 Hyon Lee,2 Seong Soo A An,1 John Hulme11Department of BioNano Technology, Gachon University, Seongnam-si 461-701, Republic of Korea; 2Department of Neurology, Gachon University Gil Medical Center, Incheon, South KoreaAbstract: Clostridium difficile (C. difficile) is rapidly becoming one of the most prevalent health care–associated bacterial infections in the developed world. The emergence of new, more virulent strains has led to greater morbidity and resistance to standard therapies. The bacterium is readily transmitted between people where it can asymptomatically colonize the gut environment, and clinical manifestations ranging from frequent watery diarrhea to toxic megacolon can arise depending on the age of the individual or their state of gut dysbiosis. Several inexpensive approaches are shown to be effective against virulent C. difficile in research settings such as probiotics, fecal microbiota transfer and immunotherapies. This review aims to highlight the current advantages and limitations of the aforementioned approaches with an emphasis on recent studies.Keywords: antibiotics, fecal matter transfer, polyclonal adjuvants, C. difficile, biotherapeutic agents |
| first_indexed | 2024-12-11T16:47:27Z |
| format | Article |
| id | doaj.art-6a50e6a5fb5a4ffa8481bbde15cc0705 |
| institution | Directory Open Access Journal |
| issn | 1178-6973 |
| language | English |
| last_indexed | 2024-12-11T16:47:27Z |
| publishDate | 2019-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Infection and Drug Resistance |
| spelling | doaj.art-6a50e6a5fb5a4ffa8481bbde15cc07052022-12-22T00:58:11ZengDove Medical PressInfection and Drug Resistance1178-69732019-06-01Volume 121597161546378Recent advances in the treatment of C. difficile using biotherapeutic agentsGiau VVLee HAn SSAHulme JVo Van Giau,1 Hyon Lee,2 Seong Soo A An,1 John Hulme11Department of BioNano Technology, Gachon University, Seongnam-si 461-701, Republic of Korea; 2Department of Neurology, Gachon University Gil Medical Center, Incheon, South KoreaAbstract: Clostridium difficile (C. difficile) is rapidly becoming one of the most prevalent health care–associated bacterial infections in the developed world. The emergence of new, more virulent strains has led to greater morbidity and resistance to standard therapies. The bacterium is readily transmitted between people where it can asymptomatically colonize the gut environment, and clinical manifestations ranging from frequent watery diarrhea to toxic megacolon can arise depending on the age of the individual or their state of gut dysbiosis. Several inexpensive approaches are shown to be effective against virulent C. difficile in research settings such as probiotics, fecal microbiota transfer and immunotherapies. This review aims to highlight the current advantages and limitations of the aforementioned approaches with an emphasis on recent studies.Keywords: antibiotics, fecal matter transfer, polyclonal adjuvants, C. difficile, biotherapeutic agentshttps://www.dovepress.com/recent-advances-in-the-treatment-of-c-difficile-using-biotherapeutic-a-peer-reviewed-article-IDRantibioticsfecal matter transferpolyclonal adjuvantsC. difficilebiotherapeutic agents |
| spellingShingle | Giau VV Lee H An SSA Hulme J Recent advances in the treatment of C. difficile using biotherapeutic agents Infection and Drug Resistance antibiotics fecal matter transfer polyclonal adjuvants C. difficile biotherapeutic agents |
| title | Recent advances in the treatment of C. difficile using biotherapeutic agents |
| title_full | Recent advances in the treatment of C. difficile using biotherapeutic agents |
| title_fullStr | Recent advances in the treatment of C. difficile using biotherapeutic agents |
| title_full_unstemmed | Recent advances in the treatment of C. difficile using biotherapeutic agents |
| title_short | Recent advances in the treatment of C. difficile using biotherapeutic agents |
| title_sort | recent advances in the treatment of c difficile using biotherapeutic agents |
| topic | antibiotics fecal matter transfer polyclonal adjuvants C. difficile biotherapeutic agents |
| url | https://www.dovepress.com/recent-advances-in-the-treatment-of-c-difficile-using-biotherapeutic-a-peer-reviewed-article-IDR |
| work_keys_str_mv | AT giauvv recentadvancesinthetreatmentofcdifficileusingbiotherapeuticagents AT leeh recentadvancesinthetreatmentofcdifficileusingbiotherapeuticagents AT anssa recentadvancesinthetreatmentofcdifficileusingbiotherapeuticagents AT hulmej recentadvancesinthetreatmentofcdifficileusingbiotherapeuticagents |